- •Non-invasive miRNA-based tests could be used for differential diagnosis.
- •Exosomal microRNAs (miRNAs) in serum are promising biomarker candidates for PSP.
- •Serum samples were analyzed with RT-qPCR to measure levels of selected miRNAs.
- •Differential miRNAs were dysregulated between patients groups and healthy controls.
Parkinson's disease (PD), a progressive neurodegenerative disease, can be misdiagnosed with atypical conditions such as Progressive Supranuclear Paralysis (PSP) due to overlapping clinical features. MicroRNAs (miRNAs) are small non-coding RNAs with a key role in post-transcriptional gene regulation. The aim was to identify a set of differential exosomal miRNAs biomarkers, which may aid in diagnosis.
We analyzed the serum level of 188 miRNAs in a discovery set, by using RTqPCR based TaqMan assay, in a small cohort of healthy controls, PD and PSP patients. Subsequently, the differentially expressed miRNAs, between PSP and PD patients, were further tested in a larger and independent cohort of 33 healthy controls, 40 PD and 20 PSP patients. The most accurate diagnostic exosomal miRNAs classifiers were identified in a logistic regression model.
A statistically significant set of three exosomal miRNAs: miR-21-3p, miR-22-3p and miR-223-5p, discriminated PD from HC (area under the curve of 0.75), and a set of three exosomal miRNAs, miR-425-5p, miR-21-3p, and miR-199a-5p, discriminated PSP from PD with good diagnostic accuracy (area under the curve of 0.86). Finally, the classifier that best discriminated PSP from PD consisted of six exosomal miRNAs (area under the curve = 0.91), with diagnostic sensitivity and specificity of 0.89 and 0.90, respectively.
Based on our analysis, these data showed that exosomal miRNAs could act as biomarkers to differentiate between PSP and PD.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Parkinsonism & Related Disorders
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- MDS clinical diagnostic criteria for Parkinson's disease.Mov. Disord. 2015; 30: 1591-1601
- Movement Disorder Society-endorsed PSP Study Group, Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria.Mov. Disord. 2017; 32: 853-864
- Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases.Cell. Mol. Neurobiol. 2013; 33: 601-613
- Noncoding RNAs in the brain.J. Neurosci. 2007; 27: 11856-11859
- Understanding microRNAs in neurodegeneration.Nat. Rev. Neurosci. 2009; 10: 837-841
- MicroRNAs and deregulated gene expression networks in neurodegeneration.Brain Res. 2010; 1338: 48-57
- A MicroRNA feedback circuit in midbrain dopamine neurons.Science. 2007; 317: 1220-1224
- Variation in the microRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein.Am. J. Hum. Genet. 2008; 82: 283-289
- Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153.J. Biol. Chem. 2010; 285: 12726-12734
- microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP).Neurogenetics. 2016; 17: 165-171
- Plasma-based circulating MicroRNA biomarkers for Parkinson's disease.J. Parkinson Dis. 2012; 2: 321-331
- Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology.PLoS One. 2014; 9e94839
- A panel of four decreased serum microRNAs as a novel biomarker for early Parkinson's disease.Biomarkers. 2016; 21: 129-137
- Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood.J. Extracell. Vesicles. 2014; 3
- Altered microRNA profiles in cerebrospinal fluid exosome in Parkinson disease and Alzheimer disease.Oncotarget. 2015; 6: 37043-37053
- Movement disorder society UPDRS revision task force. Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results.Mov. Disord. 2008; 23: 2129-2170
- A clinical rating scale for progressive supranuclear palsy.Brain. 2007; 130: 1552-1565
- DIANA-miRPath v3.0: deciphering microRNA function with experimental support.Nucleic Acids Res. 2015; 43: 460-466
- miRTarBase: a database curates experimentally validated microRNA-target interactions.Nucleic Acids Res. 2011; 39: D163-D169
- Movement Disorder Society-endorsed PSP Study Group. Radiological biomarkers for diagnosis in PSP: where are we and where do we need to be?.Mov. Disord. 2017; 32: 955-971
- Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches.Lancet Neurol. 2017; 16: 552-563
- In vivo evidence for decreased scyllo-inositol levels in the supplementary motor area of patients with Progressive Supranuclear Palsy: a proton MR spectroscopy study.Park. Relat. Disord. 2019; 62: 185-191
- Automated MRI classification in progressive supranuclear palsy: a large international cohort study.Mov. Disord. 2020; 35: 976-983
- A new MRI measure to early differentiate progressive supranuclear palsy from de novo Parkinson's disease in clinical practice: an international study.Mov. Disord. 2021; 36: 681-689
- Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells.Nat. Cell Biol. 2007; 9: 654-659
- Exosomal miRNAs as potential diagnostic biomarkers in alzheimer's disease.Pharmaceuticals. 2020; 13: 243
- The evolving landscape of exosomes in neurodegenerative diseases: exosomes characteristics and a promising role in early diagnosis.Int. J. Mol. Sci. 2021; 22: 440
- Roles of non-coding RNAs as novel diagnostic biomarkers in Parkinson's disease.J. Parkinsons. 2021; 11: 1475-1489
- CNS-derived blood exosomes as a promising source of biomarkers: opportunities and challenges.Front. Mol. Neurosci. 2020; 19: 38
- MicroRNA biomarkers of Parkinson's disease in serum exosome-like microvesicles.Neurosci. Lett. 2017; 644: 94-99
Published online: November 23, 2021
Accepted: November 18, 2021
Received in revised form: November 16, 2021
Received: June 21, 2021
© 2021 Elsevier Ltd. All rights reserved.